Codiak BioSciences - About the company
Codiak BioSciences is a public company based in Cambridge (United States), founded in 2015 by Douglas E Williams. It operates as a Developer of exosome-based drugs and diagnostics for cancer treatment. Codiak BioSciences has raised $168M in funding from Arch Venture Partners and Flagship Pioneering. The company has 2604 active competitors, including 886 funded and 648 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Guardant Health and Sana Biotechnology.
Company Details
Developer of exosome-based drugs and diagnostics for cancer. The company has developed natural vesicles that mediate intercellular communication which is used for therapeutics and diagnostic solutions. The company has developed exoSTING solid tumors for treating cancer diseases. The company's other products include exoIL-12 for melanoma, exoASO-STAT3 used to treat hematologic and hepatic cancers.
- Website
- codiakbio.com
- Social
- Email ID
- *****@codiakbio.com
- Phone Number
- +1 **********
- Registered Address
- Cambridge, Massachusetts
Key Metrics
Founded Year
2015
Location
Cambridge, United States
Stage
Public
Total Funding
$168M in 3 rounds
Latest Funding Round
Investors
Ranked
215th among 2604 active competitors
Annual Revenue
$10M - $50M as on Dec 31, 2021
Employee Count
50 - 199 as on Mar 01, 2026
Exit Details
Public
Legal entities associated with Codiak BioSciences
Codiak BioSciences is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Codiak Biosciences, Inc. CIN: 1659352 , United States, Active | $10M - $50M (As on Dec 31, 2021) | 48 (As on Dec 31, 2022) | - |
Codiak BioSciences's IPO details
Codiak BioSciences got listed on Oct 14, 2020.
Click here to take a look at Codiak BioSciences's IPO in detail
Sign up to download Codiak BioSciences' company profile
Codiak BioSciences's funding and investors
Codiak BioSciences has raised a total funding of $168M over 3 rounds. Its first funding round was on Nov 25, 2015. Its latest funding round was a Series C round on Nov 29, 2017 for $*****. 10 investors participated in its latest round. Codiak BioSciences has 12 institutional investors.
Here is the list of recent funding rounds of Codiak BioSciences:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Nov 29, 2017 | 9562232 | Series C | 3981562 | 8102066 | 6370841 | 6389490 |
Jan 26, 2016 | 3127368 | Series B | 4497208 | 6202821 | 5752594 | |
Nov 25, 2015 | 6267560 | Series A | 9293339 | 5238970 |
Access funding benchmarks and valuations. Sign up today!View details of Codiak BioSciences's funding rounds and investors
Codiak BioSciences' founders and board of directors
Founder? Claim ProfileThe founders of Codiak BioSciences is Douglas E Williams.
Here are the details of Codiak BioSciences' key team members:
- Douglas E Williams: Co-Founder of Codiak BioSciences.
View details of Codiak BioSciences's Founder profiles and Board Members
Codiak BioSciences' employee count trend
Codiak BioSciences has 50 - 199 employees as of Mar 26. Here is Codiak BioSciences's employee count trend over the years:
Uncover Codiak BioSciences' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Codiak BioSciences's Competitors and alternates
Top competitors of Codiak BioSciences include Jazz Pharmaceuticals, Guardant Health and Sana Biotechnology. Here is the list of Top 10 competitors of Codiak BioSciences, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 79/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
6th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
7th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
8th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
9th | _1545299782322.png?devicePixelRatio=2&height=30&width=30){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
10th |  Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 71/100 | |
215th | Codiak BioSciences 2015, Cambridge (United States), Public | Developer of exosome-based drugs and diagnostics for cancer treatment | $168M | 57/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Codiak BioSciences's competitors? Click here to see the top ones
Codiak BioSciences's Investments and acquisitions
Codiak BioSciences has made no investments or acquisitions yet.
Reports related to Codiak BioSciences
Here is the latest report on Codiak BioSciences's sector:
News related to Codiak BioSciences
Filter this list•
Cash-strapped biotech firm Codiak files for bankruptcy protectionMed Ad News•Mar 27, 2023•Codiak BioSciences
•
ATUM Announces Leap-In Transposase® Licensing Agreement with Codiak Biosciences to Support Manufacturing of Exosome-Based TherapeuticsBusiness Wire•Jan 24, 2023•Atum, Codiak BioSciences
•
Codiak BioSciences drops 31% postmarket on proposed stock offeringSeeking Alpha•Sep 13, 2022•Codiak BioSciences, Jefferies
•
Codiak BioSciences Announces Program Reprioritization and Corporate RestructuringGlobeNewswire•Aug 30, 2022•Codiak BioSciences
•
Codiak to get up to $2.5M from CEPI to develop broadly protective COVID vaccineSeeking Alpha•Jul 05, 2022•Codiak BioSciences, CEPI
•
Codiak begins dosing in early-stage trial for liver, gastric, colorectal cancersSeeking Alpha•Jun 29, 2022•Codiak BioSciences
•
Codiak BioSciences GAAP EPS of -$0.36 beats by $0.44, revenue of $12.7M beats by $6.4MSeeking Alpha•May 05, 2022•Codiak BioSciences
•
Codiak BioSciences rises 7% post-market after revenue soars 383% YoYSeeking Alpha•Mar 11, 2022•Codiak BioSciences
•
Data from Codiak’s exoASO™-STAT6 Preclinical Development Program for the Treatment of Primary and Metastatic Hepatic Cancers Published in Science AdvancesGlobeNewswire•Feb 19, 2022•Codiak BioSciences
•
FDA clears Codiak Bio's exoASO-STAT6 application in liver cancerSeeking Alpha•Nov 30, 2021•Codiak BioSciences
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Codiak BioSciences
Explore our recently published companies
- Adapt Design - Ventura based, 2018 founded, Unfunded company
- Audacia - Washington based, 2015 founded, Unfunded company
- Telco Communications - India based, 2012 founded, Unfunded company
- The Fragrance Lady - Grand Prairie based, Unfunded company
- entire studios - United States based, 2020 founded, Unfunded company
- Destiny Sscience - India based, 2000 founded, Unfunded company
